Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.
Kolluri KK, Alifrangis C, Kumar N, Ishii Y, Price S, Michaut M, Williams S, Barthorpe S, Lightfoot H, Busacca S, Sharkey A, Yuan Z, Sage EK, Vallath S, Le Quesne J, Tice DA, Alrifai D, von Karstedt S, Montinaro A, Guppy N, Waller DA, Nakas A, Good R, Holmes A, Walczak H, Fennell DA, Garnett M, Iorio F, Wessels L, McDermott U, Janes SM. Kolluri KK, et al. Among authors: tice da. Elife. 2018 Jan 18;7:e30224. doi: 10.7554/eLife.30224. Elife. 2018. PMID: 29345617 Free PMC article.
Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists.
Grinkevitch V, Wappett M, Crawford N, Price S, Lees A, McCann C, McAllister K, Prehn J, Young J, Bateson J, Gallagher L, Michaut M, Iyer V, Chatzipli A, Barthorpe S, Ciznadija D, Sloma I, Wesa A, Tice DA, Wessels L, Garnett M, Longley DB, McDermott U, McDade SS. Grinkevitch V, et al. Among authors: tice da. Mol Cancer Ther. 2022 Apr 1;21(4):594-606. doi: 10.1158/1535-7163.MCT-21-0532. Mol Cancer Ther. 2022. PMID: 35086954 Free PMC article.
MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE, Gilbert SF, Gril B, Narwal R, Peacock Brooks DL, Tice DA, Steeg PS, Lipkowitz S. Greer YE, et al. Among authors: tice da. Breast Cancer Res. 2019 Feb 18;21(1):27. doi: 10.1186/s13058-019-1116-1. Breast Cancer Res. 2019. PMID: 30777098 Free PMC article.
Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.
Zhong H, Chen C, Tammali R, Breen S, Zhang J, Fazenbaker C, Kennedy M, Conway J, Higgs BW, Holoweckyj N, Raja R, Harper J, Pierce AJ, Herbst R, Tice DA. Zhong H, et al. Among authors: tice da. Mol Cancer Ther. 2019 Jan;18(1):89-99. doi: 10.1158/1535-7163.MCT-18-0314. Epub 2018 Oct 23. Mol Cancer Ther. 2019. PMID: 30352801
A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.
Zhong H, Davis A, Ouzounova M, Carrasco RA, Chen C, Breen S, Chang YS, Huang J, Liu Z, Yao Y, Hurt E, Moisan J, Fung M, Tice DA, Clouthier SG, Xiao Z, Wicha MS, Korkaya H, Hollingsworth RE. Zhong H, et al. Among authors: tice da. Cancer Res. 2016 Jan 15;76(2):480-90. doi: 10.1158/0008-5472.CAN-15-0883. Epub 2016 Jan 7. Cancer Res. 2016. PMID: 26744529
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.
Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, Fazenbaker C, Fleming R, Swamynathan S, Meyer D, Senter PD, Gao C, Wu H, Kinch M, Coats S, Kiener PA, Tice DA. Jackson D, et al. Among authors: tice da. Cancer Res. 2008 Nov 15;68(22):9367-74. doi: 10.1158/0008-5472.CAN-08-1933. Cancer Res. 2008. PMID: 19010911
113 results